Immunotherapy has changed the course of blood cancers and melanomas, but is stubbornly ineffective for the treatment of most epithelial solid cancers—the cancers that kill about 90% of the more than 600,000 Americans who die of cancer each year.
In the fiscal year 2026 budget request, the Trump administration proposes “forward funding,” or multiyear funding, of awards.
